BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 27, 2024
See today's BioWorld
Home
» 'New chapter' as Geron lands potential $935M imetelstat deal with Janssen
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
'New chapter' as Geron lands potential $935M imetelstat deal with Janssen
Nov. 17, 2014
By
Michael Fitzhugh
No Comments
Geron Corp.'s savior has arrived, with Janssen Biotech Inc. pledging $35 million up front plus $900 million in potential milestone payments for an exclusive license to the company's sole pipeline asset, imetelstat.
BioWorld